标题
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
作者
关键词
-
出版物
ONCOGENE
Volume 40, Issue 28, Pages 4625-4651
出版商
Springer Science and Business Media LLC
发表日期
2021-06-18
DOI
10.1038/s41388-021-01863-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
- (2021) Keunchil Park et al. LUNG CANCER
- The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program
- (2021) Thomas Aparicio et al. Targeted Oncology
- Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC
- (2020) Gonzalo Recondo et al. CLINICAL CANCER RESEARCH
- A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.
- (2020) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET
- (2020) Feng Du et al. ONCOGENE
- The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
- (2020) Haiyu Wang et al. Frontiers in Cell and Developmental Biology
- Noncoding Microdeletion in Mouse Hgf Disrupts Neural Crest Migration into the Stria Vascularis, Reduces the Endocochlear Potential, and Suggests the Neuropathology for Human Nonsyndromic Deafness DFNB39
- (2020) Robert J. Morell et al. JOURNAL OF NEUROSCIENCE
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma
- (2020) Li Ren Kong et al. Nature Communications
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway
- (2020) Hao Peng et al. Annals of Translational Medicine
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired MET D1228N mutations mediate crizotinib resistance in lung adenocarcinoma with ROS1 fusion: a case report
- (2020) Yu Wang et al. ONCOLOGIST
- Safety and Tolerability of c-MET Inhibitors in Cancer
- (2019) Alberto Puccini et al. DRUG SAFETY
- Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
- (2019) Ilaria Saltarella et al. Journal of Hematology & Oncology
- C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
- (2019) Paulina Marona et al. Cells
- Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells
- (2019) Linlin Chang et al. Acta Pharmaceutica Sinica B
- Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis
- (2019) Jian‐feng Yao et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
- (2019) Hui Li et al. GASTROENTEROLOGY
- Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
- (2019) Sabrina Baltschukat et al. CLINICAL CANCER RESEARCH
- The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
- (2019) Xing Huang et al. Autophagy
- Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
- (2019) Li Che et al. GUT
- Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma
- (2019) Jean-Charles Nault et al. HEPATOLOGY
- c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
- (2019) Alexander Lux et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MET in glioma: signaling pathways and targeted therapies
- (2019) Fangling Cheng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
- (2019) Jordi Bertran-Alamillo et al. Nature Communications
- Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
- (2019) D Moro-Sibilot et al. ANNALS OF ONCOLOGY
- MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma
- (2019) Yiru Zhang et al. CANCER RESEARCH
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
- (2019) Toshihiko Doi et al. INVESTIGATIONAL NEW DRUGS
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
- (2018) D Westover et al. ANNALS OF ONCOLOGY
- IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway
- (2018) Wei-Chieh Huang et al. BMC CANCER
- Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis
- (2018) Fei Xing et al. CANCER RESEARCH
- c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
- (2018) Su Jin Lee et al. Clinical Colorectal Cancer
- A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers
- (2018) Aflah Roohullah et al. INVESTIGATIONAL NEW DRUGS
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
- (2018) Yu Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
- (2018) Huy Gia Vuong et al. LUNG CANCER
- Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer
- (2018) Mengqin Shen et al. Molecular Cancer
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
- (2018) Jung Han Kim et al. Journal of Cancer
- Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α
- (2018) Bin Yan et al. EXPERIMENTAL CELL RESEARCH
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
- (2018) Yi-Long Wu et al. Journal of Thoracic Oncology
- Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis
- (2018) Vit Vsiansky et al. Scientific Reports
- Targeting Cancer Stemness in the Clinic: From Hype to Hope
- (2018) Caner Saygin et al. Cell Stem Cell
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma
- (2018) Yosuke Kubo et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
- (2018) Neal Ready et al. Journal of Thoracic Oncology
- First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
- (2017) Jordi Rodon et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
- (2017) Chien-Hung Gow et al. LUNG CANCER
- Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
- (2017) Petr Szturz et al. ORAL ONCOLOGY
- Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer
- (2017) Arman Jahangiri et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Road to stemness in hepatocellular carcinoma
- (2017) Teresita NJ Flores-Téllez et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer
- (2017) Takahiro Tsuji et al. Oncotarget
- Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis
- (2017) Jung Han Kim et al. Oncotarget
- Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Evaluation of Intratumoral and Intertumoral Heterogeneity of MET Protein Expression in Gastric Cancer
- (2017) Jiwoon Choi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Cancer Stem Cells: Basic Concepts and Therapeutic Implications
- (2016) Dany Nassar et al. Annual Review of Pathology-Mechanisms of Disease
- Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis
- (2016) Fang Wang et al. BREAST
- MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
- (2016) Daniel V. T. Catenacci et al. CANCER
- The prospect of precision therapy for renal cell carcinoma
- (2016) Chiara Ciccarese et al. CANCER TREATMENT REVIEWS
- Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis
- (2016) Jifeng Peng et al. DISEASE MARKERS
- HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
- (2016) Gaofeng Fan et al. GENES & DEVELOPMENT
- Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
- (2016) Matthew Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
- (2016) Xuewen Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
- (2016) NATURE MEDICINE
- Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis
- (2016) Jung-Soo Pyo et al. PATHOLOGY RESEARCH AND PRACTICE
- Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein
- (2015) Anna C. Navis et al. ACTA NEUROPATHOLOGICA
- Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma
- (2015) Lu Dai et al. BLOOD
- Induction of tumor initiation is dependent on CD44s in c-Met+ hepatocellular carcinoma
- (2015) Hien Dang et al. BMC CANCER
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases
- (2015) Shunchao Yan et al. Diagnostic Pathology
- Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor
- (2015) Ana-Iris Schiefer et al. HISTOPATHOLOGY
- Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy
- (2015) Hyori Kim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A mutation ofMET, encoding hepatocyte growth factor receptor, is associated with humanDFNB97hearing loss
- (2015) Ghulam Mujtaba et al. JOURNAL OF MEDICAL GENETICS
- Metabolic pathways promoting cancer cell survival and growth
- (2015) Lindsey K. Boroughs et al. NATURE CELL BIOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Prognostic value of c-Met in colorectal cancer: A meta-analysis
- (2015) Yan Liu WORLD JOURNAL OF GASTROENTEROLOGY
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression
- (2015) Klaudia Skrzypek et al. Oncotarget
- Cancer metastases: challenges and opportunities
- (2015) Xiangming Guan Acta Pharmaceutica Sinica B
- RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas
- (2014) Zhao-Shi Bao et al. GENOME RESEARCH
- The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival
- (2014) Qing-le Liang et al. MEDICAL ONCOLOGY
- Expression of growth-regulated oncogene-1, hepatocyte growth factor, platelet-derived growth factor-AA and soluble E-selectin and their association with high-risk human papillomavirus infection in squamous cell carcinoma of the uterine cervix
- (2014) YE ZHANG et al. Molecular Medicine Reports
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells
- (2014) Prakash Rath et al. Translational Oncology
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers
- (2013) Do Joong Park et al. ANNALS OF SURGICAL ONCOLOGY
- High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
- (2013) F Zagouri et al. BRITISH JOURNAL OF CANCER
- α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells
- (2013) Hiromitsu Michikoshi et al. CANCER LETTERS
- Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
- (2013) L. Goyal et al. CLINICAL CANCER RESEARCH
- Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes
- (2013) Mizuho Nakayama et al. CYTOKINE
- HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
- (2013) E. Penuel et al. MOLECULAR CANCER THERAPEUTICS
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
- (2013) M. F. Burbridge et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
- (2013) S. Corso et al. Cancer Discovery
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- MET Signaling Regulates Glioblastoma Stem Cells
- (2012) K. M. Joo et al. CANCER RESEARCH
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
- (2012) Shunsuke Kondo et al. International Journal of Clinical Oncology
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
- (2011) Q. Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype
- (2011) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
- (2010) Yoshinari Asaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
- (2010) I. J. Davis et al. CANCER RESEARCH
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
- (2010) Sara Previdi et al. EUROPEAN JOURNAL OF CANCER
- Wnt activity defines colon cancer stem cells and is regulated by the microenvironment
- (2010) Louis Vermeulen et al. NATURE CELL BIOLOGY
- Noncoding Mutations of HGF Are Associated with Nonsyndromic Hearing Loss, DFNB39
- (2009) Julie M. Schultz et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
- (2009) S. Krishnaswamy et al. CLINICAL CANCER RESEARCH
- Disease-dependent reciprocal phosphorylation of serine and tyrosine residues of c-Met/HGF receptor contributes disease retardation of a transgenic mouse model of ALS
- (2009) Keiichi Kadoyama et al. NEUROSCIENCE RESEARCH
- Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?
- (2008) Elizabeth Charytonowicz et al. CANCER LETTERS
- Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma
- (2008) Erina Nakamura et al. CANCER SCIENCE
- Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer
- (2008) A. Gupta et al. CLINICAL CANCER RESEARCH
- Expression and mutational analysis ofMETin human solid cancers
- (2008) Patrick C. Ma et al. GENES CHROMOSOMES & CANCER
- Crypt stem cells as the cells-of-origin of intestinal cancer
- (2008) Nick Barker et al. NATURE
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started